|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() |
SundayBREAKING NEWS: FDA delays decision on Biogen's multiple sclerosis drug Plegridy
Biogen Idec Inc said the U.S. Food and Drug Administration extended the review process for the company's multiple sclerosis drug by three months to evaluate the application. Biogen, which was expecting to launch the drug, Plegridy, by mid-2014, said the FDA did not ask for additional studies.
Plegridy, is an injectable drug designed to reduce the dosing schedule of standard interferon drugs such as Biogen's own Avonex, which are typically dosed at least once a week. Interferon is hard to tolerate as it leads to flu-like symptoms, prompting patients to delay or discontinue treatment. Analysts say the market for such interferon-based treatments will shrink over the next decade as newer generation products enter the fray. More
Labels: Avonex |